Back to Search
Start Over
Regulating autologous stem cell interventions in Australia: updated review of the direct-to-consumer advertising restrictions.
- Source :
-
Australian Health Review . 2021, Vol. 45 Issue 4, p507-515. 9p. - Publication Year :
- 2021
-
Abstract
- Objective. This paper provides an update and overview of the law governing direct-to-consumer (DTC) advertising of autologous stem cell interventions (ASCIs) in Australia. It follows significant changes to the advertising regulations made in 2018. Methods. The paper reviews the three primary sources or 'centres' of law regulating ASCIs in Australia, together with the relevant guidance documents that supplement these sources. It provides analysis of how the post-2018 advertising regulations, contained in the Therapeutic Goods Act 1989 (Cwlth), apply to all 'biologicals', including ASCIs. It demonstrates how these three sources of law interact with one another and outlines the new tiered offence regime that applies to contraventions of these prohibitions. Results. The analysis demonstrates that DTC advertising of ASCIs in Australia is strictly controlled, with primary legislation prohibiting the advertising of biologicals altogether. Conclusions. The polycentric legal regime regulating biologicals in Australia clearly makes DTC advertising of ASCIs unlawful. Health practitioners who promote ASCIs, either online, in print or in other media forms, may be penalised in different ways and by different authorities. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 01565788
- Volume :
- 45
- Issue :
- 4
- Database :
- Academic Search Index
- Journal :
- Australian Health Review
- Publication Type :
- Academic Journal
- Accession number :
- 151768906
- Full Text :
- https://doi.org/10.1071/AH20217